Navigation Links
American Chemical Society's Weekly Press Pac
Date:8/27/2007

tendency for molecules to enter the skin, he said. Previously, scientists have assumed the structure of an emulsion remains intact as lotions evaporate.

ARTICLE #1 EMBARGOED FOR: Wednesday, Aug. 22, 9:00 a.m., Eastern Time

CONTACT:
Stig Friberg, Ph.D.
University of Virginia
Charlottesville, Va. 22911
Phone: 434-973-8826
E-mail: sfbg@comcast.net


ARTICLE #2 EMBARGOED FOR: Wednesday, Aug. 22, 10:45 a.m., Eastern Time

Some forms of good cholesterol can be bad for the heart

Good cholesterol, renowned for its ability to protect against heart disease, can undergo detrimental changes in protein composition that make it bad for the heart, according to a new laboratory study by researchers in Seattle, Wash.

Scientists long have suspected that there may be dysfunctional forms of so-called good cholesterol, also called high density lipoprotein (HDL) cholesterol, that can lose their heart-protective effect. But the exact chemical composition of HDL, both good forms and bad, has remained largely unknown, researchers say.

In what is believed to be the most detailed analysis to date of the protein composition of HDL, Jay Heinecke and colleagues uncovered surprising new information about HDL, including previously unrecognized proteins that appear to play an important role in maintaining heart health. Their findings could one day lead to new, more accurate lab tests for heart disease as well as new, potentially life-saving treatments for the disease, which is the number one killer in the United States and other developed countries.

Targeting HDL could represent a new horizon in heart disease diagnosis and treatment, Heinecke said. But simply boosting HDL levels may not be enough to prevent heart disease. You might have to target the right proteins in HDL.

ARTICLE #2 EMBARGOED FOR: Wednesday, Aug. 22, 10:45 a.m., Eastern
'/>"/>

Contact: Michael Woods
m_woods@acs.org
202-872-4400
American Chemical Society
Source:Eurekalert

Page: 1 2 3 4 5 6 7 8 9

Related biology news :

1. First North American Encapsulated Islet Transplant without Long-term Immune Suppression into a Patient with Type 1 Diabetes
2. Health costs soar as 60 million Americans classed as obese
3. Discovery of an American salamander where it shouldnt be: Korea
4. DNA traces evolution of extinct sabertooths and the American cheetah-like cat
5. North & South American researchers find architectural abnormalities in T. cruzi ribosome
6. T-rays: New imaging technology spotlighted by American Chemical Society
7. New peptide antibiotic isolated from American oyster
8. Computers to save unique type of American red squirrel
9. Alcoholism, smoking and genetics among Plains American Indians
10. Gene variation increases SIDS risk in African Americans
11. Americans support free access to research
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 3Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 2Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 3WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6